

# Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C438A992076EN.html>

Date: December 2019

Pages: 34

Price: US\$ 3,500.00 (Single User License)

ID: C438A992076EN

## Abstracts

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019'; Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Cathepsin S (CTSS or EC 3.4.22.27) - Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils.

The report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019' outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology, Infectious Disease and Metabolic Disorders which include indications Alzheimer's Disease, Autoimmune Disorders, Breast Cancer, Cancer Pain, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)

The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects

The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Cathepsin S (CTSS or EC 3.4.22.27) - Overview

Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development

Evotec SE

F. Hoffmann-La Roche Ltd

Fusion Antibodies Plc

Virobay Inc

Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles

Fsn-0503h - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5461111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-114137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cathepsin S for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-50365 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin S (CTSS or EC 3.4.22.27) - Dormant Products

Cathepsin S (CTSS or EC 3.4.22.27) - Discontinued Products

Cathepsin S (CTSS or EC 3.4.22.27) - Product Development Milestones

Featured News & Press Releases

Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease

Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Evotec SE, H2 2019

Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Pipeline by Fusion Antibodies Plc, H2 2019

Pipeline by Virobay Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Evotec SE

F. Hoffmann-La Roche Ltd

Fusion Antibodies Plc

Virobay Inc

## I would like to order

Product name: Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C438A992076EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C438A992076EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970